FY2024 Earnings Estimate for REGN Issued By Leerink Partnrs

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Investment analysts at Leerink Partnrs boosted their FY2024 earnings estimates for shares of Regeneron Pharmaceuticals in a research note issued to investors on Tuesday, January 28th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings per share of $38.10 for the year, up from their previous forecast of $37.10. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $37.73 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q2 2025 earnings at $7.92 EPS, Q3 2025 earnings at $9.57 EPS and Q4 2025 earnings at $9.27 EPS.

A number of other research analysts have also weighed in on the company. Citigroup cut their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Royal Bank of Canada decreased their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Finally, BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Trading Down 0.6 %

Shares of Regeneron Pharmaceuticals stock opened at $683.08 on Wednesday. The firm has a market capitalization of $75.06 billion, a price-to-earnings ratio of 16.90, a PEG ratio of 1.59 and a beta of 0.10. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm’s 50 day simple moving average is $723.36 and its two-hundred day simple moving average is $928.61. Regeneron Pharmaceuticals has a 12-month low of $666.25 and a 12-month high of $1,211.20.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Rakuten Securities Inc. increased its stake in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $26,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $37,000. Private Wealth Management Group LLC raised its stake in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 39 shares during the last quarter. Finally, Truvestments Capital LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $39,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.